F.C. Aldighieri

STANDARDIZATION OF REFERENCE VALUES FOR THYROID UPTAKE USING I-123

D. E. Blanco

DOSIMETRY IN THE THERAPY WITH 131-I OF A PATIENT WHO REQUIRES DIALYSIS TREATMENT

O.J. Degrossi

AGGRESSIVE BEHAVIOUR OF WELL DIFFERENTIATED THYROID CARCINOMA (DTC) STAGES I AND II. TEN YEAR FOLLOW UP.

E. Dziuk

RADIATION RISK TO PATIENTS TREATED FOR VARIOUS THYROID DISEASES WITH IODINE-131

I.S. Endo

RELATIONSHIP BETWEEN EFFECTIVE HALF-LIFE AND THE AGE OF 434 PATIENTS WITH THYROID CARCINOMA TREATED WITH RADIOACTIVE IODINE-131

S.G. Gerali

USEFULLNESS OF ABLATION DOSE OF 131I IN PATIENTS WITH DIFFERENTIATED THYROID CANCER WITH HIGH 131I UPTAKE DUE TO SUBTOTAL THYROIDECTOMY

P. González-Cabezas

HYPERPARATHYROIDISM TREATMENT : 99MTC-SESTAMIBI PARATHYROID SCINTIGRAPHY AND INTRAOPERATIVE DETERMINATION OF PARATHYROID INTACT HORMONE.

J. Hahn

AUTOMATED OBJECTIVE THYROID ABLATION DOSE CALCULATIONS UNSING INTERACTIVE COMPUTER PROGRAM

THYROGLOBULIN RECOVERY TEST OF SERA CONTAINING ELEVATED LEVELS OF ANTI-THYROBLOBULIN ANTIBODIES

T. Higuchi

COMPARATIVE STUDY OF FDG-PET AND SESTAMIBI-SPECT IN THE DIAGNOSIS OF SECONDARY HYPERPARATHYROIDISM

M.J. Jofre

AN EIGHTEEN YEAR EXPERIENCE OF DIFFERENTIATED THYROID CARCINOMA TREATMENT WITH 131 RADIOIODINE AT THE MILITARY HOSPITAL NUCLEAR MEDICINE DEPATMENT.

Z.L. Li

THYROID HORMONE AUTO-ANTIBODIES INTERFERENCE IN THYROID HORMONE ASSAY

B. Llana

LOCALIZATION OF NEUROENDOCRINE TUMOURS WITH IN111-OCTREOTIDE SCINTIGRAPHY

Gr. Madeddu

THYROID FUNCTION IN HIV PATIENTS TREATED WITH HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART)

A.C.H. Nascimento

BIOKINETIC STUDY OF 131I FOLLOWING ABLATION DOSE ADMNISTRATION

Z.P. Petrovski

EFFICIENCY OF RADIOIODINE THERAPY IN GRAVES DISEASE AND ADENOMA TOXICUM AND INCIDENCE OF HYPOTHYROIDISM

J.I. Rayo

ROLE OF ADDITIONAL PIN-HOLE LATERAL VIEWS IN MIBI-TC99M PARATHYROID SCINTIGRAPHY

M.P. Sierralta

N.C. Silva

PRELIMINARY DATA ON RADIOIODINE TREATMENT OF MULTINODULAR GOITERS IN ELDERLY PATIENTS PRECEEDED BY STIMULATION WITH HUMAN RECOMBINANT TSH

L.E. Tenorio

RECOMBINANT TSH (THYROGEN) ADMINISTRATION TO A PATIENT WITH METASTATIC WELL DIFFERENTIATED THYROID CARCINOMA IN WHOM SIX WEEKS OF T-4 WITHDRAWAL LED TO A SUB-OPTIMAL TSH RESPONSE

M. B. Tomas

VALUE OF TC-99M SESTAMIBI SPECT IMAGING IN THE PREOPERATIVE LOCALIZATION OF MEDIASTINAL PARATHYROID LESIONS

P. Vlcek

DIFFERENTIATED THYROID CARCINOMA-OVERVIEW OF THE 40 YEARS EXPERIENCE

A.C. Zarlenga

SOMATOSTATIN RECEPTOR SCINTIGRAPHY (SRS) WITH 99M-TC HYNIC-TOC